

Igor Tsauro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/51470/publications.pdf>

Version: 2024-02-01

130
papers

2,528
citations

201385

27
h-index

276539

41
g-index

135
all docs

135
docs citations

135
times ranked

3809
citing authors

#	ARTICLE	IF	CITATIONS
1	Features and management of men with pN1 cMO prostate cancer after radical prostatectomy and lymphadenectomy: a systematic review of population-based evidence. <i>Current Opinion in Urology</i> , 2022, 32, 69-84.	0.9	6
2	Smartglass augmented reality-assisted targeted prostate biopsy using cognitive point-of-care fusion technology. <i>International Journal of Medical Robotics and Computer Assisted Surgery</i> , 2022, 18, e2366.	1.2	8
3	Insulin-like Growth Factor-1 Influences Prostate Cancer Cell Growth and Invasion through an Integrin $\alpha 3$, $\alpha 5$, αV , and $\beta 1$ Dependent Mechanism. <i>Cancers</i> , 2022, 14, 363.	1.7	14
4	Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway. <i>Nutrients</i> , 2022, 14, 369.	1.7	4
5	Molecular Mechanisms Related with Oligometastatic Prostate Cancer—Is It Just a Matter of Numbers?. <i>Cancers</i> , 2022, 14, 766.	1.7	2
6	Artesunate Inhibits the Growth Behavior of Docetaxel-Resistant Prostate Cancer Cells. <i>Frontiers in Oncology</i> , 2022, 12, 789284.	1.3	13
7	Biomarkers to personalize treatment with ^{177}Lu -PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210819.	1.4	12
8	High—Normal Preoperative Potassium Level Is Associated with Reduced 30—Day Morbidity and Shorter Hospital Stay after Radical Cystectomy. <i>Journal of Clinical Medicine</i> , 2022, 11, 1174.	1.0	0
9	Shikonin Inhibits Cell Growth of Sunitinib-Resistant Renal Cell Carcinoma by Activating the Necrosome Complex and Inhibiting the AKT/mTOR Signaling Pathway. <i>Cancers</i> , 2022, 14, 1114.	1.7	9
10	The timing of initial imaging in testicular cancer: impact on radiological findings and clinical decision making. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	1.3	1
11	Predictors of Unfavorable Pathology in Patients with Incidental (pT1a—T1b) Prostate Cancer. <i>European Urology Focus</i> , 2022, , .	1.6	3
12	Value of c-MET and Associated Signaling Elements for Predicting Outcomes and Targeted Therapy in Penile Cancer. <i>Cancers</i> , 2022, 14, 1683.	1.7	1
13	Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer—Current State and Future Perspectives. <i>Cancers</i> , 2022, 14, 147.	1.7	2
14	Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2022, 82, 82-96.	0.9	15
15	Amygdalin Exerts Antitumor Activity in Taxane-Resistant Prostate Cancer Cells. <i>Cancers</i> , 2022, 14, 3111.	1.7	8
16	Treatment of Metastasized Prostate Cancer Beyond Progression After Upfront Docetaxel—A Real-world Data Assessment. <i>European Urology Focus</i> , 2021, 7, 1308-1315.	1.6	3
17	Global change of surgical and oncological clinical practice in urology during early COVID-19 pandemic. <i>World Journal of Urology</i> , 2021, 39, 3139-3145.	1.2	20
18	A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?. <i>European Urology Oncology</i> , 2021, 4, 745-754.	2.6	17

#	ARTICLE	IF	CITATIONS
19	Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review. <i>European Urology Focus</i> , 2021, 7, 742-751.	1.6	19
20	Robot-assisted simple prostatectomy versus open simple prostatectomy: a single-center comparison. <i>World Journal of Urology</i> , 2021, 39, 149-156.	1.2	26
21	Determinants of self-reported functional status (EPIC-26) in prostate cancer patients prior to treatment. <i>World Journal of Urology</i> , 2021, 39, 27-36.	1.2	12
22	Immunotherapy in prostate cancer: new horizon of hurdles and hopes. <i>World Journal of Urology</i> , 2021, 39, 1387-1403.	1.2	17
23	Systemic treatment of penile squamous cell carcinoma—hurdles and hopes of preclinical models and clinical regimens: a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 4085-4098.	0.6	6
24	Shikonin Reduces Growth of Docetaxel-Resistant Prostate Cancer Cells Mainly through Necroptosis. <i>Cancers</i> , 2021, 13, 882.	1.7	35
25	Phase 2 of the Coronavirus Pandemic in Urology: Ramping Up Surgical Caseload and Resident Training while COVID-19 Infections Decrease. <i>Urologia Internationalis</i> , 2021, 105, 1-2.	0.6	2
26	Radical Prostatectomy: Sequelae in the Course of Time. <i>Frontiers in Surgery</i> , 2021, 8, 684088.	0.6	4
27	Assessment of PI3K/mTOR/AKT Pathway Elements to Serve as Biomarkers and Therapeutic Targets in Penile Cancer. <i>Cancers</i> , 2021, 13, 2323.	1.7	6
28	Pandemic Spread of COVID-19 Mutant Variants Will Facilitate Next-generation Sequencing Capacities for Personalised Medicine in Urologic Oncology. <i>European Urology</i> , 2021, 79, 895-896.	0.9	0
29	Robotic surgery can be safely performed for patients and healthcare workers during COVID-19 pandemic. <i>International Journal of Medical Robotics and Computer Assisted Surgery</i> , 2021, 17, e2291.	1.2	3
30	Focal Therapy for Prostate Cancer: Complications and Their Treatment. <i>Frontiers in Surgery</i> , 2021, 8, 696242.	0.6	13
31	Radiation Therapy After Radical Prostatectomy: What Has Changed Over Time?. <i>Frontiers in Surgery</i> , 2021, 8, 691473.	0.6	5
32	A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer. <i>Cancer Medicine</i> , 2021, 10, 6354-6364.	1.3	7
33	Nivolumab Reduces PD1 Expression and Alters Density and Proliferation of Tumor Infiltrating Immune Cells in a Tissue Slice Culture Model of Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 4511.	1.7	5
34	Deciphering the Molecular Machinery—Influence of sE-Cadherin on Tumorigenic Traits of Prostate Cancer Cells. <i>Biology</i> , 2021, 10, 1007.	1.3	0
35	The timing of initial imaging in testicular cancer: impact on radiological findings and clinical decision making. <i>Minerva Urology and Nephrology</i> , 2021, , .	1.3	0
36	Making surgery safer by centralization of care: impact of case load in penile cancer. <i>World Journal of Urology</i> , 2020, 38, 1385-1390.	1.2	21

#	ARTICLE	IF	CITATIONS
37	Application of Dried Human Amnion Graft to Improve Post-Prostatectomy Incontinence and Potency: A Randomized Exploration Study Protocol. <i>Advances in Therapy</i> , 2020, 37, 592-602.	1.3	10
38	Risk factors and molecular characterization of penile cancer. <i>Current Opinion in Urology</i> , 2020, 30, 202-207.	0.9	11
39	Trends in urologic oncology clinical practice and medical education under COVID-19 pandemic: An international survey of senior clinical and academic urologists. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 929.e1-929.e10.	0.8	7
40	Initial Experience with Radical Prostatectomy Following Holmium Laser Enucleation of the Prostate. <i>European Urology Focus</i> , 2020, 7, 1247-1253.	1.6	7
41	Outreach and Influence of Surgical Societies'™ Recommendations on Minimally Invasive Surgery During the COVID-19 Pandemic'™An Anonymized International Urologic Expert Inquiry. <i>Urology</i> , 2020, 145, 73-78.	0.5	2
42	Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer. <i>PLoS ONE</i> , 2020, 15, e0237248.	1.1	11
43	Utility of Minimally Invasive Technology for Inguinal Lymph Node Dissection in Penile Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 2501.	1.0	7
44	Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review. <i>European Urology Oncology</i> , 2020, 3, 565-581.	2.6	46
45	Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction. <i>Cells</i> , 2020, 9, 2643.	1.8	63
46	Towards data-driven medical imaging using natural language processing in patients with suspected urolithiasis. <i>International Journal of Medical Informatics</i> , 2020, 137, 104106.	1.6	15
47	Use of psycho'™oncological services by prostate cancer patients: A multilevel analysis. <i>Cancer Medicine</i> , 2020, 9, 3680-3690.	1.3	11
48	AR-V7 Protein Expression in Circulating Tumour Cells Is Not Predictive of Treatment Response in mCRPC. <i>Urologia Internationalis</i> , 2020, 104, 253-262.	0.6	4
49	Telemedicine Online Visits in Urology During the COVID-19 Pandemic'™Potential, Risk Factors, and Patients'™ Perspective. <i>European Urology</i> , 2020, 78, 16-20.	0.9	168
50	External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection. <i>European Urology</i> , 2020, 78, 138-142.	0.9	55
51	Imaging modalities in synchronous oligometastatic prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 2573-2583.	1.2	16
52	Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies?. <i>World Journal of Urology</i> , 2019, 37, 243-251.	1.2	37
53	Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 999-1005.	0.8	7
54	Hereditary prostate cancer '™ Primetime for genetic testing?. <i>Cancer Treatment Reviews</i> , 2019, 81, 101927.	3.4	20

#	ARTICLE	IF	CITATIONS
55	Mechanisms behind Temsirolimus Resistance Causing Reactivated Growth and Invasive Behavior of Bladder Cancer Cells In Vitro. <i>Cancers</i> , 2019, 11, 777.	1.7	7
56	Influence of the HDAC Inhibitor Valproic Acid on the Growth and Proliferation of Temsirolimus-Resistant Prostate Cancer Cells In Vitro. <i>Cancers</i> , 2019, 11, 566.	1.7	14
57	sE-cadherin is upregulated in serum of patients with renal cell carcinoma and promotes tumor cell dissemination in vitro. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 355.e1-355.e9.	0.8	1
58	Development of symptomatic lymphoceles after radical prostatectomy and pelvic lymph node dissection is independent of surgical approach: a single-center analysis. <i>International Urology and Nephrology</i> , 2019, 51, 633-640.	0.6	20
59	Aggressive variants of prostate cancer – “Are we ready to apply specific treatment right now?”. <i>Cancer Treatment Reviews</i> , 2019, 75, 20-26.	3.4	23
60	Risk factors, complications and management of lymphocele formation after radical prostatectomy: A mini-review. <i>International Journal of Urology</i> , 2019, 26, 711-716.	0.5	22
61	CT-guided nephrostomy – “An expedient tool for complex clinical scenarios. <i>European Journal of Radiology</i> , 2019, 110, 142-147.	1.2	4
62	Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2019, 76, 493-504.	0.9	111
63	Websites on Bladder Cancer: an Appropriate Source of Patient Information?. <i>Journal of Cancer Education</i> , 2019, 34, 381-387.	0.6	13
64	Immune check point inhibitors for metastatic urothelial carcinoma: current evidence-based approach for urology daily practice. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 205-216.	3.9	1
65	Are clinical guidelines designed according to guidelines? Cross-sectional assessment of quality and transparency of clinical guidelines in urology. <i>World Journal of Urology</i> , 2018, 36, 1489-1494.	1.2	1
66	Nationwide analysis on the impact of socioeconomic land use factors and incidence of urothelial carcinoma. <i>Cancer Epidemiology</i> , 2018, 52, 63-69.	0.8	6
67	AR-V7 predicting treatment response in metastasized prostate cancer: has it peaked?. <i>World Journal of Urology</i> , 2018, 36, 149-151.	1.2	1
68	Testicular Cancer on the Web – “an Appropriate Source of Patient Information in Concordance with the European Association of Urology Guidelines?. <i>Journal of Cancer Education</i> , 2018, 33, 1314-1322.	0.6	9
69	Aggressive variant and treatment-related neuroendocrine prostate cancer: two different terms for the same disease?. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 297-300.	0.3	0
70	Combining anticancer drugs with osteoprotective agents in prostate cancer – “A contemporary update. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 488-497.	0.8	0
71	Focal therapy in localised prostate cancer: Real-world urological perspective explored in a cross-sectional European survey. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 529.e11-529.e22.	0.8	31
72	HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression. <i>Cells</i> , 2018, 7, 129.	1.8	19

#	ARTICLE	IF	CITATIONS
73	How can we expand active surveillance criteria in patients with low and intermediate risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator. <i>BJU International</i> , 2018, 122, 823-830.	1.3	27
74	Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival. <i>International Urology and Nephrology</i> , 2018, 50, 1821-1827.	0.6	12
75	Acquired resistance to temsirolimus is associated with integrin $\alpha 7$ driven chemotactic activity of renal cell carcinoma <i>in vitro</i> . <i>Oncotarget</i> , 2018, 9, 18747-18759.	0.8	3
76	Prostate Cancer on the Web – Expedient Tool for Patients’ Decision-Making?. <i>Journal of Cancer Education</i> , 2017, 32, 135-140.	0.6	44
77	Strategy of robotic surgeons to exert public influence through Twitter. <i>International Journal of Medical Robotics and Computer Assisted Surgery</i> , 2017, 13, e1739.	1.2	2
78	Incidence, Risk Factors and Management of Symptomatic Lymphoceles after Radical Retropubic Prostatectomy. <i>Urology Practice</i> , 2017, 4, 493-498.	0.2	4
79	Ruptured angiomyolipoma of the kidney: a rare differential diagnosis of flank pain. <i>Scandinavian Journal of Urology</i> , 2017, 51, 342-344.	0.6	2
80	Hidradenitis suppurativa gains increasing interest on World Wide Web: a source for patient information?. <i>International Journal of Dermatology</i> , 2017, 56, 726-732.	0.5	18
81	mTOR inhibition reduces growth and adhesion of hepatocellular carcinoma cells <i>in vitro</i> . <i>Molecular Medicine Reports</i> , 2017, 16, 7064-7071.	1.1	11
82	HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells. <i>Oncotarget</i> , 2017, 8, 110016-110028.	0.8	17
83	What should be the patient’s preference regarding the choice of hospital in the case of radical cystectomy? Evaluation of early complications after open radical cystectomy in a medium and high volume setting in one hospital. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 2181-2187.	0.8	5
84	Online Discussion on #KidneyStones: A Longitudinal Assessment of Activity, Users and Content. <i>PLoS ONE</i> , 2016, 11, e0160863.	1.1	20
85	Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned. <i>Dentistry Journal</i> , 2016, 4, 28.	0.9	3
86	Robotic Prostatectomy on the Web: A Cross-Sectional Qualitative Assessment. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e355-e362.	0.9	13
87	Rare Case of Excessive Beta-Human Chorionic Gonadotropin Producing Intrascrotal Leiomyosarcoma: Diagnostic Pitfalls and Therapeutic Implications. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e409-e412.	0.9	1
88	Activity, content, contributors, and influencers of the twitter discussion on urologic oncology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 377-383.	0.8	44
89	R.E.N.A.L. Score Outperforms PADUA Score, C-Index and DAP Score for Outcome Prediction of Nephron Sparing Surgery in a Selected Cohort. <i>Journal of Urology</i> , 2016, 196, 664-671.	0.2	44
90	Amygdalin inhibits the growth of renal cell carcinoma cells <i>in vitro</i> . <i>International Journal of Molecular Medicine</i> , 2016, 37, 526-532.	1.8	32

#	ARTICLE	IF	CITATIONS
91	Amygdalin delays cell cycle progression and blocks growth of prostate cancer cells in vitro. Life Sciences, 2016, 147, 137-142.	2.0	45
92	Amygdalin blocks the in vitro adhesion and invasion of renal cell carcinoma cells by an integrin-dependent mechanism. International Journal of Molecular Medicine, 2016, 37, 843-850.	1.8	17
93	Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro. Oncotarget, 2016, 7, 85208-85219.	0.8	23
94	Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion. Oncotarget, 2016, 7, 20410-20424.	0.8	7
95	Evaluation of TKTL1 as a biomarker in serum of prostate cancer patients. Central European Journal of Urology, 2016, 69, 247-251.	0.2	7
96	TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer. International Journal of Oncology, 2015, 47, 857-866.	1.4	69
97	Utilization of surgical safety checklists by urological surgeons in Germany: a nationwide prospective survey. Patient Safety in Surgery, 2015, 9, 37.	1.1	5
98	PCA3 and PSA gene activity correlates with the true tumor cell burden in prostate cancer lymph node metastases. Cancer Biomarkers, 2015, 15, 311-316.	0.8	5
99	Feasibility, complications and oncologic results of a limited inguinal lymph node dissection in the management of penile cancer. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2015, 41, 486-495.	0.7	15
100	Intensified antineoplastic effect by combining an HDAC inhibitor, an mTOR inhibitor and low dosed interferon alpha in prostate cancer cells. Journal of Cellular and Molecular Medicine, 2015, 19, 1795-1804.	1.6	11
101	E-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients. Journal of Experimental and Clinical Cancer Research, 2015, 34, 43.	3.5	27
102	Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib. Journal of Cellular and Molecular Medicine, 2015, 19, 430-441.	1.6	24
103	CCL2 promotes integrin-mediated adhesion of prostate cancer cells in vitro. World Journal of Urology, 2015, 33, 1051-1056.	1.2	6
104	CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study. Cancer Research and Treatment, 2015, 47, 306-312.	1.3	52
105	Novel survey disseminated through Twitter supports its utility for networking, disseminating research, advocacy, clinical practice and other professional goals. Canadian Urological Association Journal, 2015, 9, 713.	0.3	55
106	Cross-communication between histone H3 and H4 acetylation and Akt/mTOR signalling in prostate cancer cells. Journal of Cellular and Molecular Medicine, 2014, 18, 1460-1466.	1.6	27
107	Direct lymphangiography as treatment option of lymphatic leakage: Indications, outcomes and role in patient's management. European Journal of Radiology, 2014, 83, 2167-2171.	1.2	45
108	HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A. Molecular Cancer, 2014, 13, 152.	7.9	42

#	ARTICLE	IF	CITATIONS
109	Resistance to the mTOR Inhibitor Temsirolimus Alters Adhesion and Migration Behavior of Renal Cell Carcinoma Cells through an Integrin $\alpha 5 \beta 1$ and Integrin $\alpha 3 \beta 1$ Dependent Mechanism. <i>Neoplasia</i> , 2014, 16, 291-300.	2.3	18
110	Amygdalin Blocks Bladder Cancer Cell Growth In Vitro by Diminishing Cyclin A and cdk2. <i>PLoS ONE</i> , 2014, 9, e105590.	1.1	64
111	Amygdalin Influences Bladder Cancer Cell Adhesion and Invasion In Vitro. <i>PLoS ONE</i> , 2014, 9, e110244.	1.1	34
112	The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258. <i>Investigational New Drugs</i> , 2013, 31, 265-272.	1.2	10
113	Resistance after Chronic Application of the HDAC-Inhibitor Valproic Acid Is Associated with Elevated Akt Activation in Renal Cell Carcinoma In Vivo. <i>PLoS ONE</i> , 2013, 8, e53100.	1.1	35
114	Expression of Foxp3 in Colorectal Cancer but Not in Treg Cells Correlates with Disease Progression in Patients with Colorectal Cancer. <i>PLoS ONE</i> , 2013, 8, e53630.	1.1	74
115	Chemokines involved in tumor promotion and dissemination in patients with renal cell cancer. <i>Cancer Biomarkers</i> , 2012, 10, 195-204.	0.8	8
116	Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells. <i>Cancer Letters</i> , 2012, 324, 83-90.	3.2	40
117	Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion. <i>Prostate</i> , 2012, 72, 1719-1735.	1.2	22
118	Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis. <i>BMC Cancer</i> , 2011, 11, 375.	1.1	25
119	Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells. <i>Cancer Letters</i> , 2011, 301, 17-28.	3.2	16
120	The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line. <i>Cancer Letters</i> , 2011, 313, 84-90.	3.2	41
121	Corrigendum to "Tumour-mediated TRAIL-Receptor expression indicates effective apoptotic depletion of infiltrating CD8+ immune cells in clinical colorectal cancer" [European Journal of Cancer 46 (12) (2010) 2314-2323]. <i>European Journal of Cancer</i> , 2011, 47, 2373.	1.3	0
122	Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001. <i>Life Sciences</i> , 2011, 88, 418-424.	2.0	29
123	Transitional Cell Carcinoma of the Native Urinary Tract After Kidney Transplantation: Recommendations Following a Long-Term Retrospective Analysis. <i>American Journal of the Medical Sciences</i> , 2011, 341, 478-483.	0.4	17
124	HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro. <i>Anti-Cancer Drugs</i> , 2011, 22, 1002-1009.	0.7	23
125	De novo renal cell carcinoma of native and graft kidneys in renal transplant recipients. <i>BJU International</i> , 2011, 108, 229-234.	1.3	44
126	Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells. <i>Clinical and Experimental Metastasis</i> , 2011, 28, 479-491.	1.7	47

#	ARTICLE	IF	CITATIONS
127	Donor antigen-specific regulatory T-cell function affects outcome in kidney transplant recipients. <i>Kidney International</i> , 2011, 79, 1005-1012.	2.6	21
128	Association of Intravesical Tumor Location With Metastases to the Pelvic Lymph Nodes in Transitional Cell Cancer of the Bladder. <i>American Journal of the Medical Sciences</i> , 2010, 339, 341-344.	0.4	12
129	Development of urological cancers in renal transplant recipients: 30-year experience at the Frankfurt Transplant Center. <i>Cancer Science</i> , 2010, 101, 2430-2435.	1.7	34
130	Tumour-mediated TRAIL-Receptor expression indicates effective apoptotic depletion of infiltrating CD8+ immune cells in clinical colorectal cancer. <i>European Journal of Cancer</i> , 2010, 46, 2314-2323.	1.3	27